

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.



LING YUI HOLDINGS LIMITED
凌銳控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 784)

APPOINTMENT OF TWO EXECUTIVE DIRECTORS

The Board hereby announces that with effect from 11 May 2026, Dr. Xu Mingyan and Dr. Chen Shifu have been appointed as executive Directors.

Reference is made to the composite offer and response document dated 5 May 2026 (the “**Composite Document**”) jointly issued by Hapbiotech Investment Holding Limited and Ling Yui Holdings Limited (the “**Company**”) in relation to the Offer. Unless the context otherwise requires, capitalised terms in this joint announcement shall have the same meanings as defined in the Composite Document.

The board of directors (the “**Board**”) is pleased to announce that with effect from 11 May 2026, Dr. Xu Mingyan (許明炎) (“**Dr. Xu**”) and Dr. Chen Shifu (陳實富) (“**Dr. Chen**”) have been appointed as executive Directors.

The biographical details of Dr. Xu and Dr. Chen are as follows:

Dr. Xu Mingyan (許明炎)

Dr. Xu Mingyan (許明炎), aged 43, founded HI Group with other founders in September 2014, has been a director of HI since November 2021 and was re-designated as its executive director in February 2023. He is primarily responsible for the overall operations and management of HI Group. Prior to that, he served as a scientist in Cambrian Genomics Inc., a biotechnology company mainly engaged in using laser-based technique to synthesize deoxyribonucleic acid (DNA) from January 2013 to July 2014, where he was principally responsible for research and development.

Dr. Xu received a bachelor’s degree in chemistry from Nanchang University (南昌大學) in Jiangxi Province, the PRC in June 2005 and a master’s degree in inorganic chemistry from Beijing Normal University (北京師範大學) in Beijing, the PRC in June 2008. He also received a doctoral degree in biomedical science from The University of New Mexico in Albuquerque, New Mexico, the US in July 2013.

Dr. Xu has entered into a letter of appointment with the Company, pursuant to which Dr. Xu agreed to act as an executive Director for a term of three years commencing from 11 May 2026, which may be terminated by either party giving no less than one month's written notice to the other party. Dr. Xu will hold office until the forthcoming annual general meeting of the Company and be eligible for re-election at that meeting pursuant to the memorandum and articles of association of the Company. According to the letter of appointment, Dr. Xu is entitled to a director's fee of HK\$360,000 per annum, and shall be entitled to participate in the Company's stock option scheme on terms as shall be adopted by the Company from time to time and discretionary payment and other benefits that his position is entitled from the Company as from time to time in force, which was determined by the Board based on the recommendation of the remuneration committee of the Company with reference to, among other things, his qualifications, experience, responsibilities and prevailing market conditions.

Dr. Chen Shifu (陳實富)

Dr. Chen Shifu (陳實富), aged 41, founded HI Group with other founders in September 2014, has been a director of HI since January 2023 and was re-designated as its executive Director in February 2023. He is primarily responsible for product research and development, academic research and the establishment of diagnostic development system of HI Group. Prior to that, from June 2010 to October 2014, he consecutively served as a CUDA Technical Consultant and senior software engineer principally responsible for CUDA parallel computing and software development in NVIDIA Semiconductor (Shenzhen) Co., Ltd. (英偉達半導體(深圳)有限公司), a company principally engaged in manufacturing and development of artificial intelligence hardware and software and the shares of its parent company NVIDIA Corporation are listed on the NASDAQ (NASDAQ: NVDA).

Dr. Chen received a bachelor's degree in mathematics and applied mathematics from Nanchang University (南昌大學) in Jiangxi Province, the PRC in August 2005 and a master's degree in computer software and theory from Institute of Computing Technology, Chinese Academy of Sciences (中國科學院計算技術研究所) in Beijing, the PRC in July 2010. He also received a doctoral degree in pattern recognition and intelligent systems Shenzhen Institute of Advanced Technology (深圳先進技術研究院) established by Chinese Academy of Sciences (中國科學院) in Guangdong Province, the PRC in January 2018.

Dr. Chen has entered into a letter of appointment with the Company, pursuant to which Dr. Chen agreed to act as an executive Director for a term of three years commencing from 11 May 2026, which may be terminated by either party giving no less than one months' written notice to the other party. Dr. Chen will hold office until the forthcoming annual general meeting of the Company and be eligible for re-election at that meeting pursuant to the memorandum and articles of association of the Company. According to the letter of appointment, Dr. Chen is entitled to a director's fee of HK\$360,000 per annum, and shall be entitled to participate in the Company's stock option scheme on terms as shall be adopted by the Company from time to time and discretionary payment and other benefits that his position is entitled from the Company as from time to time in force, which was determined by the Board based on the recommendation of the remuneration committee of the Company with reference to, among other things, his qualifications, experience, responsibilities and prevailing market conditions.

As at the date of this announcement, the Offeror is interested in a total of 560,140,000 Shares, representing 70.02% of the total issued share capital of the Company, and the entire issued share capital of which is beneficially owned by HI.

By virtue of the SFO, each of Dr. Xu and Dr. Chen, being one of the Concert Parties (which include the spouse of Dr. Xu, who is indirectly interested in 3.14% of the shareholding in HI), is deemed to be interested in the aggregate shareholding of 43.28% in HI as held by the controlled corporations of the Concert Parties, and as such, Dr. Xu and Dr. Chen are deemed to be interested in the 560,140,000 Shares held by the Offeror.

As at the date of this announcement, save as disclosed above, each of Dr. Xu and Dr. Chen (i) does not hold any other positions in the Company or any other members of the Group; (ii) did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years prior to the date of this announcement; (iii) does not have any other interests or short positions in any shares, underlying shares or debentures within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationships with any Directors, senior management, substantial shareholders, or controlling shareholders of the Company as defined in the Listing Rules.

Save as disclosed above, there is no other information relating to the appointment of each of Dr. Xu and Dr. Chen that needs to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Dr. Xu and Dr. Chen to the Board.

By order of the Board
Ling Yui Holdings Limited
Ling Chi Fai
Chairman and Executive Director

Hong Kong, 11 May 2026

As at the date of this joint announcement, the Board comprises Mr. Ling Chi Fai, Mr. Leung Cheuk Ho, Dr. Xu Mingyan and Dr. Chen Shifu as executive Directors; Mr. Ling Yuk Tong as a non-executive Director; and Mr. Chong Kam Fung, Mr. Ho Chun Chung Patrick, Mr. Shi Wai Lim William and Ms. Yau Suk Man as independent non-executive Directors.